Distribution of molecular abnormalities in patients with therapy-related (t-AML) and de novo AML exhibiting a normal karyotype
| . | t-AML, n (%) . | de novo AML, n (%) . | P . |
|---|---|---|---|
| NPM1 mutation | 16/40 (40) | 537/1067 (50) | .26 |
| FLT3-ITD | 10/39 (26) | 348/1054 (33) | .39 |
| CEBPA mutation | 2/29 (7) | 98/894 (11) | .76 |
| FLT3-TKD mutation | 3/33 (9) | 87/982 (9) | > .999 |
| MLL-PTD | 2/27 (7) | 57/848 (7) | .70 |
| . | t-AML, n (%) . | de novo AML, n (%) . | P . |
|---|---|---|---|
| NPM1 mutation | 16/40 (40) | 537/1067 (50) | .26 |
| FLT3-ITD | 10/39 (26) | 348/1054 (33) | .39 |
| CEBPA mutation | 2/29 (7) | 98/894 (11) | .76 |
| FLT3-TKD mutation | 3/33 (9) | 87/982 (9) | > .999 |
| MLL-PTD | 2/27 (7) | 57/848 (7) | .70 |
AML indicates acute myeloid leukemia; ITD, internal tandem duplication; PTD, partial tandem duplication; and TKD, tyrosine kinase domain.